A small desk with a strict standard.
NAD Picks is an independent review desk covering NAD⁺ — the injections, IV drips, nasal sprays, patches and oral precursors people are sold, and the companies selling them. We exist because the gap between what the trials show and what NAD⁺ is marketed as is enormous, and because in this category the cheapest option happens to have the best evidence behind it — which is not what most of the internet will tell you.
NAD Picks has no parent company and no outside owner. Our writers publish under consistent pen names — a common practice in health and science journalism — so that the work is judged on its sourcing rather than on personality. Bylines are stable: the same name always means the same writer, and every claim is anchored to a citation you can check yourself.
Medical and scientific accuracy is verified against primary sources before anything is published. For clinical content we are building a panel of licensed reviewers; review status is stated honestly on each piece, and we never attach credentials we cannot stand behind.
The desk
Julian Roth
Research & dataTrials, effect sizes, and the primary literature.
View profile →Nadia Feldman
Access & costCost, coverage, access pathways, and side-effect timelines.
View profile →Priya Anand
Pharmacology & mechanismsReceptors, half-lives, drug interactions, and where mechanism outruns evidence.
View profile →Theo Lindqvist
Peptides & longevityPeptides, NAD+, senolytics, and healthspan — graded by human evidence.
View profile →Read more about how we work in our methodology and disclosures.